← Back to Clinical Trials
Recruiting NCT06393894

NCT06393894 Latvian Early Atherosclerosis Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06393894
Status Recruiting
Phase
Sponsor Pauls Stradins Clinical University Hospital
Condition Coronary Artery Disease
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2019-04-01
Primary Completion 2030-12-31

Trial Parameters

Condition Coronary Artery Disease
Sponsor Pauls Stradins Clinical University Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2019-04-01
Completion 2030-12-31
Interventions
Near infrared spectroscopyGenetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Atherosclerosis and its complications are a global problem. There are several widely known and proven risk factors that promotes atherogenesis in the majority of patients. However, significant proportion of apparently healthy and young patients with cardiovascular disease but yet without recognized atherogenesis promoting risk factors can be observed in clinical practice. It highlights the need of new risk markers for early atherosclerosis diagnostics to prevent serious cardiovascular complications in these patients and in population in general. The interest in the negative impact of genetic variance, gene regulation on atherogenesis is growing. Therefore the purpose of this study is to analyze the impact of genetic variance and microRNA expression on early atherosclerosis development in the population of young, apparently healthy patients with coronary atherosclerosis. The primary hypothesis is that the group of patients with premature atherosclerosis have common genetic variations promoting early atherosclerosis development. The secondary hypothesis is that specific circulating microRNA expression (miR-126, miR-145 and miR-155) correlate with plaque lipid core by near infrared spectroscopy (NIRS) analysis.

Eligibility Criteria

Inclusion criteria: * Signed informed consent * Early atherosclerosis defined as coronary atherosclerosis in men aged \<55 years and women \<65 years * Coronary artery atherosclerosis with angiographically proven coronary vessel luminal stenosis ≥ 50% and ischaemia * Coronary artery atherosclerosis with planned revascularization * History of coronary artery revascularization (PTCA or coronary artery bypass surgery) * Coronary vessel suitable for NIRS pullback Exclusion criteria: * Diabetes * Total cholesterol ≥7 mmol/l and/or LDL ≥ 5 mmol/l * family hypercholesterolemia * positive family history of early cardiovascular disease (myocardial infarction, sudden cardiac death or cardiovascular disease of first degree relatives at young age - men \<55 years, women \<65 years) * malignant or resistant hypertension ≥ 10 years * body mass index ≥40 kg/m 2 ) * 20 or more pack years of smoking

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology